Company: SGBAF
Filing Date: 2025-04-01
Form Type: DRS/A
Source: 0000950123-25-003272
Chunk: 372

Company: SES S.A.
Filing Date: 2025-04-01
Form: DRS/A
Chunk 372
---
 parties The state of Luxembourg holds a direct 11.58% voting interest in the Company and two indirect interests, both of 10.88% each, through two state owned banks, Banque et Caisse d’Epargne de l’Etat and Société Nationale de Crédit et d’Investissement and is therefore deemed to have a significant influence over the Company. These shares constitute the Company’s Class B shares, as described in Note 24. In 2024 the Company generated revenue of EUR 31 million (2023: EUR 27 million) with departments of the Government of the state of Luxembourg and held a trade receivable of EUR 0 million as of December 31, 2024 (2023: EUR 4.1 million). There were no transactions with other related parties in 2024, nor in 2023, which would require disclosure. The total remuneration paid to directors for attendance at board and committee meetings in 2024 amounted to EUR 1.2 million (2023: EUR 1.2 million, 2022: EUR 1.0 million). These amounts are computed on a fixed and variable basis, the variable part being based upon attendance at board and committee meetings. The key management of the Group, defined as the Senior Leadership Team, received compensation as follows:

| € million                                          |     | 2024 |    |     | 2023 |    |     | 2022 |    |
| Remuneration including bonuses and other benefits* |     |      |  8 |     |      | 10 |     |      |  7 |
| Share-based compensation plans                     |     |      |  2 |     |      |  1 |     |      |  3 |
| Total                                              |     |      | 10 |     |      | 11 |     |      | 10 |

| * | 2024 remuneration of SLT members includes EUR 0 million (2023: EUR 1.6 million) of 
 contractual severance payment for departing Senior Leadership Team members         |

The total outstanding amount in respect of share-based payment instruments allocated to key management as of December 31, 2024 was 2,542,423 (2023: 3,868,807, 2022: 5,455,577). F-93

Confidential Treatment Requested by SES Pursuant to 17 C.F.R.